Stock Report

TAKE Limited delivers strong Q1 FY27 Performance

Posted On : 2026-08-11 22:27:45( TIMEZONE : IST )

TAKE Limited, a global technology-driven healthcare company, today announced its unaudited financial results for the first quarter ended June 30, 2026 (Q1 FY 2026-27). Demonstrating significant operational momentum, the Company delivered Consolidated Revenue from Operations of ₹3,037.33 Lakhs (₹30.37 Crore) and a Consolidated Net Profit of ₹106.26 Lakhs (₹1.06 Crore), reversing a Net Loss of ₹(91.00) Lakhs in the corresponding prior-year period.

KEY FINANCIAL PERFORMANCE HIGHLIGHTS (Q1 FY 2026-27)

Consolidated Revenue & Total Income: Consolidated Revenue from Operations expanded dramatically to ₹3,037.33 Lakhs compared to Nil revenue in Q1 FY26. Total Income reached ₹3,170.11 Lakhs (₹31.70 Crore), backed by commercial scaling and execution.

Profitability: Consolidated Profit Before Tax (PBT) and Net Profit After Tax (PAT) reached ₹106.26 Lakhs, marking a complete return to profitability compared to a Net Loss of ₹(91.00) Lakhs in Q1 FY26.

Finance Costs: Finance costs plummeted by 99.62% YoY to just ₹0.07 Lakhs (down from ₹17.50 Lakhs in Q1 FY26), reflecting debt elimination, interest burden reduction, and a clean capital structure.

Earnings Per Share (EPS): Basic and Diluted EPS turned positive at ₹0.07 per share (Face Value Re. 1/-), up from negative ₹(0.06) per share in Q1 FY26.

Standalone Performance: Standalone Revenue from Operations surged to ₹1,196.90 Lakhs (vs ₹0.65 Lakhs in Q1 FY26), with Net Profit turning around to ₹96.83 Lakhs (vs a Net Loss of ₹216.45 Lakhs in Q1 FY26).

"Our Q1 FY27 results reflect the successful stabilization and revitalization of TAKE Limited's operational framework. With an extremely clean balance sheet, near-zero finance costs, and profitable operations, we are now executing our next growth phase. Our strategic entry into the Longevity and Anti-Ageing sector positions TAKE Limited at the intersection of life sciences, technology, and consumer wellness. By combining our regulatory and clinical domain expertise with cutting-edge biohacking and predictive digital tools, we are building a scalable, high-margin platform that addresses the multi-billion-dollar shift toward proactive health optimization." Parmeshvar Dhangare, Director, TAKE Limited.

Shares of Take Solutions Limited was last trading in BSE at Rs. 23.26 as compared to the previous close of Rs. 22.99. The total number of shares traded during the day was 79633 in over 557 trades.

The stock hit an intraday high of Rs. 23.40 and intraday low of 22.79. The net turnover during the day was Rs. 1839656.00.